SOUTHAMPTON, England - Vantia Therapeutics, an emerging pharmaceutical company developing novel, small molecule drugs targeting large, underserved medical markets, announces positive results from a Phase IIa clinical trial of its lead development compound VA106483 for nocturia. The trial showed that oral VA106483 was successful in producing a predictable and sustained anti-diuretic effect in patients, as determined by increased osmolality and decreased urine output. The study also found that VA106483 was generally well tolerated among the patient population.
Nocturia (defined as waking frequently to urinate at night thereby disturbing sleep significantly) is a common condition, with prevalence increasing markedly with age. It is often the presenting symptom in men with benign prostatic hypertrophy (BPH) and affects at least 70% of BPH patients. There is currently no adequate treatment for nocturia and it represents a potential market estimated at more than US$500 million.
VA106483 is a novel small molecule drug candidate that exerts its effect directly in the kidney by binding to vasopressin (V2) receptors, which regulate water balance. It was discovered by Vantia from its extensive drug candidate library.
The double-blind, placebo-controlled, dose-response study was designed to investigate the pharmacodynamics and pharmacokinetics of single and repeated oral doses of VA106483. The trial involved 27 elderly men aged 65 years or more with a history of nocturia.
Based on these results, Vantia now plans to advance VA106483 into a larger Phase IIb clinical efficacy study in the second half of 2009.
Dr Jim Phillips, CEO of Vantia Therapeutics, said ‘VA106483 was discovered and has been developed by Vantia based on its small molecule drug development expertise and is the first of several potentially high-value drug candidates in our pipeline. The clinical results for VA106483 are very encouraging and we look forward to advancing it into the next stages of clinical development. These results will also further highlight the value of this new drug candidate as we progress partnership discussions in parallel. ‘
Notes to Editors:
About Vantia Therapeutics
Vantia Therapeutics is an emerging pharmaceutical company developing novel, small molecule drugs targeting large, underserved medical markets. Formed in 2008 as a spin-out of Ferring Research Ltd’s small molecule R&D, it has two clinical phase products, VA106483 for the treatment of nocturia in BPH patients and VA111913 for the treatment of dysmenorrhoea, as well as preclinical and discovery programmes based on protease inhibition with potential in the areas of oncology and inflammation. The company’s investors include MVM Life Science Partners, SV Life Sciences and Novo A/S. Vantia Therapeutics is situated on Southampton Science Park, UK, where it occupies 10,000 sq ft of chemistry and biology facilities. For further information, please go to www.vantiatherapeutics.com.
About nocturia
Nocturia (defined as waking to void at night) is a common condition, with prevalence increasing markedly with age. It is often the presenting symptom of benign prostatic hypertrophy (BPH) with at least 70% of BPH patients complaining of nocturia. Whilst some symptoms of BPH are successfully addressed by the standard BPH therapies of alpha blockers and 5-alpha reductase inhibitors, nocturia remains inadequately treated. With estimates putting the number of BPH/nocturia sufferers at 55 million in the seven largest markets world wide, and only 10% of these believed to be receiving any kind of treatment, it is a clear area of unmet medical need estimated to be worth in excess of $500m. The hormone vasopressin is involved in the regulation of the body’s water content and as a vasopressin agonist VA106483 has been shown to act as an anti-diuretic.
Contact details: Vantia Therapeutics Dr Jim Phillips, CEO, +44(0)238-076-3433 info@vantia.com, +44(0)7515-397176 Citigate Dewe Rogerson Chris Gardner, Mark Swallow, Helena Galilee, +44(0)207-638-9571 vantia@citigatedr.co.uk
Source: Vantia Therapeutics
Contact details: Vantia Therapeutics, Dr Jim Phillips, CEO, +44(0)238-076-3433, info at vantia.com, +44(0)7515-397176; Citigate Dewe Rogerson, Chris Gardner, Mark Swallow, Helena Galilee, +44(0)207-638-9571, vantia at citigatedr.co.uk
Related Press Releases
Karolinska Development Portfolio Company Completes Successful Phase II Clinical TrialSeptember 3rd, 2009 STOCKHOLM - Karolinska Development (publ) today announced that one of its portfolio companies, Dilafor AB, has concluded an extensive clinical study of its candidate drug, tafoxiparin, a new drug substance for the prevention of protracted labor during childbirth. The promising results of the Phase II trial bring the project closer to exit in line with Karolinska Development's business strategy.
EPIX Pharmaceuticals, Inc. Announces the PRX-00023 Therapeutics CNS Program in Phase 2b/3 Will Be Part of the Intellectual Property Offered for Sale at the September 30, 2009 AuctionAugust 24th, 2009 WELLESLEY HILLS, Massachusetts -
Joseph F. Finn, Jr., C.P.A.
Funxional Successfully Completes Initial Clinical Trial of FX125L, an Anti-Inflammatory Drug With a Novel Mechanism of ActionJuly 7th, 2009 CAMBRIDGE, England - Funxional Therapeutics Ltd (Funxional) has announced today the successful completion of the first Phase I study with FX125L, an orally available small molecule which belongs to a new therapeutic class named Broad Spectrum Chemokine Inhibitors (BSCIs). The Phase I, single ascending dose study was conducted in the United States.
Ludwig Institute of Cancer Research Ltd., Brussels Branch, Issues Statement Concerning Prospect Therapeutics, Inc.'s GCS-100 MoleculeJune 7th, 2009 WELLESLEY HILLS, Massachusetts - Joseph F. Finn, Jr., C.P.A.
Mersana Reports Preliminary Phase 1 Results of XMT-1001 in Patients with Advanced Solid TumorsMay 31st, 2009 CAMBRIDGE, Massachusetts - Results Presented at American Society of Clinical Oncology (ASCO) Meeting Show Fleximer(R) Conjugated Drug Is Well Tolerated with Favorable Pharmacokinetics and Prolonged Stable Disease in Refractory Tumors -
Mersana Therapeutics presented preliminary results of a Phase 1 clinical trial for its lead development candidate, XMT-1001, in a poster session at the 2009 Annual Meeting of the American Society of Clinical Oncology (ASCO) in Orlando. XMT-1001 is a broad-spectrum cytotoxic, based on camptothecin (CPT), conjugated to Mersana's biodegradable polymer platform, Fleximer(R).
Successful Phase I/II Clinical Trial Results From Cancer Patients Treated With Anti-Cancer Drug From Axelar ABMay 5th, 2009 STOCKHOLM - Axelar AB today announced successful completion of the single-day oral dosing part of its ongoing phase I/II clinical trial on cancer patients with its new anti-cancer drug AXL1717,an insulin-like growth factor-1 (IGF-1) receptor inhibitor which has no effects on the closely related insulin receptor. The study is conducted in Sweden on patients having terminal cancer disease.
Vantia Therapeutics Appoints Rachel Morten as Head of Regulatory AffairsApril 20th, 2009 SOUTHAMPTON, England - Vantia Therapeutics, a company developing novel small molecule drugs targeting large underserved medical markets, today announces the appointment of Rachel Morten as Head of Regulatory Affairs. Rachel has more than 24 years experience in global regulatory affairs and product development in the pharmaceutical and animal health industries.
Mersana's Second Development Candidate, XMT-1107, Shows Superior Pharmacokinetics and Anti-Tumor Activity in Studies Presented at American Association of Cancer Research MeetingApril 18th, 2009 CAMBRIDGE, Massachusetts - Data Show Fleximer(R) Extends Exposure to Conjugated Drug -
Mersana, a platform-based cancer therapeutics company, today announced positive results of preclinical studies for its second development candidate, XMT-1107, in two posters at the 2009 Annual Meeting of the American Association of Cancer Research (AACR) in Denver. The studies showed that XMT-1107, a novel anti-angiogenic fumagillin analog conjugated to Mersana's proprietary Fleximer(R), demonstrated superior anti-tumor activity in tumor xenograft models in comparison to other anti-angiogenic agents and extended exposure to the conjugated drug, supporting the potential clinical utility of XMT-1107 as an anti-cancer agent.
Vantia Therapeutics' Pipeline Continues to MatureMarch 23rd, 2009 SOUTHAMPTON, England - VA106483 Completes Phase IIa Trial and VA111913 Completes Phase I
Dosing
Vantia Therapeutics, a company focusing on first-in-class
therapies for unmet medical needs, announces further clinical trial progress
with its two lead development compounds, VA106483 for nocturia associated
with benign prostatic hypertrophy (BPH) and VA111913 for dysmenorrhoea. The
Phase IIa trial of VA106483 has completed, while dosing is complete in the
Phase I trial of VA111913.
ThromboGenics Announces Business Update and 2008 Full Year ResultsMarch 11th, 2009 LEUVEN, Belgium - ThromboGenics Reports Pre-Tax Profit of EUR12.2 Million For 2008
ThromboGenics NV (Euronext Brussels: THR), a biotechnology
company focused on the discovery and development of innovative treatments
that will make a real difference to patient care in a number of important
therapeutic areas, is today issuing a business update and its financial
results for the full year ending December 31, 2008. During the last twelve months, ThromboGenics has made
considerable progress across all aspects of its business culminating in the
recent start of the Phase III clinical development program for its lead
product microplasmin in back of the eye disease.
Related News
United Therapeutics says its board approves stock split that will take effect Sept. 23September 1st, 2009 United Therapeutics approves 2-for-1 stock splitSILVER SPRING, Md. — Biotechnology company United Therapeutics Corp.
Cell Therapeutics offering more than 29.3 million shares of stock, 7.3 million warrantsJuly 23rd, 2009 Cell Therapeutics offering stock, warrantsSEATTLE — Biotechnology company Cell Therapeutics Inc. said Wednesday it will publicly offer just over 29.3 million shares of common stock and about 7.3 million shares of warrants to buy common stock.
Minn. judge halts state court action on Williams case pending federal hearingAugust 5th, 2009 Williamses' case halted in Minn. courtST. PAUL, Minn. — Minnesota Vikings linemen Kevin and Pat Williams can play this season unless a federal court gets involved and backs the NFL's bid to suspend them for violating anti-doping rules.
NFL, NFLPA warn players drug-testing program still in effect despite StarCaps lawsuitSeptember 22nd, 2009 NFL reminds players about drug-testing programNFL players have been warned the league's drug-testing program is still in effect despite commissioner Roger Goodell's ruling to delay suspending several players who tested positive for a banned substance. In a joint memo issued in the past two weeks by Goodell and NFL Players Association executive director DeMaurice Smith, players were reminded in bold print that they will continue to be tested as in the past and "a positive test will generally result in a suspension."
The memo was obtained by The Associated Press on Tuesday.
Women identify more closely with positive stereotypes, performance-wiseMay 4th, 2009 WASHINGTON - Women identify more closely with positive stereotypes, avoiding the harmful effect that negative ones can have on their performance, says a new study. The study, led by Robert J.
NATO warships to visit Pakistan, SingaporeMarch 26th, 2009 BRUSSELS - NATO warships will for the first time visit South East Asia, including Pakistan and Singapore later this month, the 26-member alliance has said here in a statement. 'The deployment of warships in South East Asia demonstrates the high value NATO places on its relationship with other partners across the globe.
74 candidates file papers in second phase of West Bengal pollsApril 16th, 2009 KOLKATA - A total of 74 nominations have been filed for the second phase of Lok Sabha elections in 17 of the 42 constituencies of West Bengal till Thursday. The maximum nominations - seven - have been received for the Krishnanagar and Uluberia seats, while only one candidate each filed papers for the Kanthi and Asansol seats.
Judge expected to rule by Aug. 7 in NFL drug policy case against 2 Vikings linemenJuly 22nd, 2009 Judge to rule by Aug. 7 in Vikings suspensionsMINNEAPOLIS — Minnesota Vikings linemen Kevin Williams and Pat Williams will have to wait a bit longer to find out if they will be going to trial before the season begins.
Asparagus extracts may fight hangover, protect the liverAugust 15th, 2009 WASHINGTON - Asparagus extract contains amino acids and minerals, which may ease alcohol hangover and protect liver cells against toxins, according to a study. Asparagus officinalis is a common vegetable that is widely consumed worldwide, and has long been used as an herbal medicine due to its anticancer effects.
Minn. judge halts state action in Vikings suspension case pending federal rulingAugust 5th, 2009 Vikings' suspensions case awaits federal rulingST. PAUL, Minn. — Minnesota Vikings linemen Kevin and Pat Williams still don't know if they'll be suspended by the NFL in their dispute over its anti-doping policy, but the fight won't be in state court any time soon — if at all.
